Venture capital fund · 12 deals
Sydney, NSW
Every published round OneVentures took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
Companies OneVentures has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| AMP | 11 Mar 2025 | 1 | 0 | |
| BuildKite | 17 Nov 2022, Series B | 1 | 1 | |
| Employment Hero | Another Australian company backed by TCV | 2018, Series B | 3 | 0 |
| Eucalyptus | 27 Jan 2022, Series C | 1 | 0 | |
| Hivery | startup that offers AI-driven retail strategy simulation and optimisation solutions tools… | 15 Jul 2022, Series B | 1 | 0 |
| Hometime | Australia’s largest short-term rental property management company | 2019 | 1 | 0 |
| Kepler Analytics | 23 Feb 2022, Series B | 1 | 1 | |
| MyPass | Global contractor credentials platform for worker onboarding, compliance and credentials … | 17 Feb 2025, Series A | 1 | 1 |
| Vaxxas | Biotech/MedTech company | 9 Dec 2022 | 2 | 1 |
Companies OneVentures's own portfolio page lists that no published round yet places it in. The page is the source; the round is being looked for.
| Company | Site |
|---|---|
| 6clicks | - |
| AmazingCo | - |
| BiVACOR | - |
| Biza.io | - |
| BuildingIQ | - |
| Cascade | - |
| Charm Health | - |
| Coassemble | - |
| Dataweavers | - |
| Drawboard | - |
| EatClub | - |
| Edrolo | - |
| etrainu | - |
| Find-Me Technologies | - |
| Fleet Space Technologies | - |
| Flippa | - |
| Investor Log in | dynamo.dynamosoftware.com ↗ |
Investors that coverage says has money in a fund OneVentures runs. This is a stake in the fund, not in any company the fund has backed.
| Investor | Fund | Sources |
|---|---|---|
| Australian Government | OneVentures Innovation Fund I | Brandon Capital, Brandon BioCatalyst portfolio, Brandon Capital portfolio (19 Jan 2023), Brandon Capital portfolio (9 Nov 2022) |
| OneVentures | Venture Growth Fund | Women's Agenda, SmartCompany |
| Victorian Government | Venture Growth Fund | Women's Agenda, SmartCompany |
This is a stake in the fund itself, money that the fund's manager invests, not a stake in the fund manager.
| Fund | Manager | Sources |
|---|---|---|
| Venture Growth Fund | OneVentures | Women's Agenda, SmartCompany |
Companies OneVentures has backed that another company then bought. An exit for the holding, not a deal OneVentures did.
| Company | Bought by | Kind | Announced | Price |
|---|---|---|---|---|
| Eucalyptus | Hims & Hers | Acquisition | Jan 2026 | US$1.2b (A$1.7b) |
Stories naming OneVentures. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
ASIC filings show Buildkite raised $21m via convertible debt in January 2026 after heavy losses and a CEO change; its earlier backers include OneVentures, AirTree, General Catalyst and Dom Pym.
Also Capital Brief
Roundup of six Australian funding deals: AutoGrab, Applied EV, Checkbox, Hometime, Factory and On the House, with amounts, investors, and Hometime's past acquisitions and raise history detailed.
Also Startup Daily
Sydney short-stay property manager Hometime has secured $19 million in fresh equity and debt, led by Verona Capital with Commonwealth Bank refinancing; the piece also recounts earlier raises and three rival acquisitions.
Curated OneVentures roundup: Eucalyptus sold to a New York-listed healthcare group for $1.6 billion and Vaxxas named ex-Merck vaccines president David Peacock as CEO, plus patent-cliff and women-in-tech links.
Weekly roundup detailing five Australian raises: Vaxxas' Series D plus debt facility amid executive changes, Skutopia's growth round, Send Payments' backing and CEO change, Apate.ai's seed, and Coursebox's seed.
Also Startup Daily·SmartCompany·Australian FinTech·Dealroom·Startup Daily
Australian biotech Vaxxas secured a Series D plus a debt facility while overhauling leadership: a new chair, founding CEO shifting to an advisory role, and CFO made redundant amid job cuts.
Also Business News Australia·SmartCompany·Cut Through Venture·Startup Daily·Startup Daily·SmartCompany·Startup Daily
Vaxxas announced a roughly A$90m financing — Series D equity led by SPRIM Global Investments plus debt — to advance its needle-free vaccine patch, alongside leadership changes including a new chair.
A OneVentures blog post flags an artificial heart developer it has backed as out soliciting fresh capital; the text provided names no company, investors, or completed round.
AFR reports the titanium artificial heart maker is chasing $100 million for trials after a Sydney patient spent three months on the device; OneVentures is named as a backer.
E-commerce software firm AMP raised $20 million from Openspace Ventures and OneVentures and bought Back in Stock, a Shopify restocking app, adding its 25,000 customers; its 2023 Series A was $29.5 million.
Sydney workforce-credential platform MyPass Global has closed a $7.5 million Series A round led by venture firm OneVentures, with funds earmarked for product development and growth across the Americas.
Weekly roundup of seven Australian and New Zealand raises totalling $42.8 million, spanning property-investment AI, workforce credentialing, allied-health practice software, conversation analytics, maths learning games, copper processing and holiday-park bookings.
Seek is selling part of its Employment Hero holding to KKR for $95m, implying a $2.2bn valuation; the article also recalls the HR startup's Series F and its buyouts of Humi and Employment Innovations.
Workforce credentialing platform MyPass has secured $7.5 million in Series A backing from OneVentures to grow across the Americas and further build its Skills Passport product. Scalare Partners seeded the company in 2020.
Also SmartCompany
Vaxxas wins US$2 million as a concept-stage winner of BARDA's prize to advance its skin-patch vaccine platform with UQ's BASE facility; the article also recalls early backing by OneVentures, Brandon Capital and HealthCare Ventures.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·@AuManufacturing·@AuManufacturing·Business News Australia
Employment Hero acquires Canada's Humi for $112m and, filings show, paid $43.4m for Ben Thompson's Employment Innovations; the story also recalls its 2023 Series F and investor clash.
A OneVentures blog stub links to Capital Brief's report that the venture firm is approaching a major growth milestone, has added key staff, and is preparing a fresh fund.
SYNthesis BioVentures' third investor letter reports a roughly A$7.5m first close for Alzheimer's biotech S2N, lists co-investors, and profiles managing director Amir's career across OneVentures, Ceres Capital and other life-sciences roles.
The venture firm's own post says it is out raising for a new vehicle to fill space corporate investors have vacated; the text states no close and no committed amount.
OneVentures' media-roundup page archives press coverage of the firm and of Employment Hero's major funding round, while its headline funds-under-management milestone remains an intention rather than a completed close.
Weekly roundup of seven trans-Tasman raises totalling $27.4 million, headlined by Xefco's $10.5 million round, plus Hometime board appointments and Matrak's China expansion.
Also Startup Daily·Startup Daily·Startup Daily·SmartCompany·Startup Daily
Buildkite announces a US$21 million Series B with Airtree and OneVentures leading; founder Keith Pitt reflects on nine years building the company, its Test Analytics product, and plans for new developer tools.
Roundup of January 2024 funding: Futurerent, Prota Therapeutics, National Renewable Network and Getmee together secured $94.5 million across debt, equity and a government grant, with investor details for each deal.
Prota Therapeutics, a Melbourne biotech, has secured $32 million in equity and debt ahead of a Phase 3 trial of its peanut allergy therapy, with Singapore's SPRIM Global Investments leading the round.
Also SmartCompany·SmartCompany·SmartCompany·Business News Australia·Forbes Australia
OneVentures realised $116.2 million selling its Employment Hero stake in a secondary deal, and its managing director Michelle Deaker is leaving the HR platform's chair role while staying on the board.
Publisher's post about a venture firm multiplying its money thirteen-fold on one startup bet; the page also carries linked reports of Eucalyptus's $1.6 billion sale and Vaxxas naming David Peacock chief executive.
US regulators cleared first-in-human testing of BiVACOR's total artificial heart; the OneVentures page also links earlier coverage and the Biomedical Translation Fund's investment in the device.
Vaxxas reports positive Phase I results for its needle-free skin-patch delivery of a measles-rubella vaccine, with Gates Foundation grant funding and a planned PATH-sponsored Phase I/II trial in The Gambia.
Employment Hero raised a $263 million Series F led by TCV, reaching a $2 billion valuation, with existing backers reinvesting; Skykraft announced a $120 million raise.
Also employmenthero.com
Australian HR software firm Employment Hero has banked a large Series F led by US investor TCV, lifting its valuation towards $2 billion, with several existing backers also taking part.
Sydney HR-and-payroll firm Employment Hero announced a TCV-led Series F reaching unicorn valuation; the profile covers its products, remote workforce and global ambitions, citing rival raises.
Partner content profiles an AI ecommerce startup that used OneVentures venture debt instead of equity to drive growth, also recalling its $10 million Series A from 2021.
OneVentures' insights page rounds up media coverage: an AFR report on Employment Hero's $263 million raise, a Forbes piece on OneVentures reaching $1 billion under management, and two AFR features on venture funding.
Vaxxas reports encouraging interim Phase I results for its needle-free microarray-patch COVID-19 vaccine, with strong antibody responses and no serious adverse events, ahead of planned regulatory applications in Australia and the US.
Vaxxas hires former Pfizer medical executive Dr Rochelle Chaiken as its chief medical officer; the announcement also recounts the biotech's founding financing and later rounds.
Vaxxas has appointed 23-year Pfizer veteran Dr Rochelle Chaiken as chief medical officer; the announcement also recaps the vaccine-patch company's early backing by OneVentures, Brandon Capital and others.
OneVentures' blog post pointing readers to Financial Review coverage of the firm and the artificial-heart developer BiVACOR; the post itself contains no deal details.
Vaxxas has begun an Australian Phase I trial of its needle-free influenza vaccine patch. The article also recalls the company's founding equity financing led by OneVentures with Brandon Capital Partners and other co-investors.
Vaxxas partners with CEPI, which will fund preclinical testing of its needle-free vaccine patch for mRNA vaccines, work that could remove cold-storage needs and widen global access to such vaccines.
Also Brandon BioCatalyst portfolio·@AuManufacturing·@AuManufacturing
A weekly roundup reporting ten Australian startup funding rounds totalling roughly eighty million dollars, spanning insurance tech, biotech, process mining, connectivity and food, with several female-founded companies among the recipients.